Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 26, 2004

View Archived Issues

MDM2 antagonists activate p53 tumor suppressor pathway in vivo

Kaneka acquires rights to tacrolimus-eluting stents from Fujisawa

New lower dose Prempro available

Lonza and NovImmune enter agreement for clinical grade monoclonal antibodies

Three series of TACE inhibitors prepared and tested at AstraZeneca

New vanilloid VR1 agonists for pain and urinary incontinence presented by Takeda

Unitech claims new leflunomide analogues with potent antiinflammatory activity

AstraZeneca describes new MEK inhibitors with utility in solid tumor therapy

New tubulin polymerization inhibitors covered by Zentaris patent

BMS scientists identify novel HIV integrase inhibitors

New synthetic isoflavone derivative inhibits asthma in vivo

Novel mutagenic desoxyribonucleoside analogue against HIV

EUK-134 directly protects human keratinocytes from UVB-induced oxidative damage

West Pharmaceutical and Pharmalink to develop IgA-nephropathy treatment

Entereg receives fast track status for postoperative ileus

Nastech's intranasal PYY3-36 spray tested in phase Ic study for obesity

Seattle Genetics and Abbott sign manufacturing agreement for SGN-30

Phase I program commences for HCV-086

APD-356 enters phase I trial for obesity

SuperGen acquires European marketing authorizations for Nipent

Intermittent dosing of Paxil CR for PMDD approved by FDA

The Medicines Company reports 2003 progress

Galen highlights Q1 developments

Lilly highlights significant R&D events over the last three months

Antihypertensive effects of ALT-711 found in patients with high SBP values

Licensees sought for attenuated influenza virus technology

Phase II results announced for DX-890 in children with cystic fibrosis

Good efficacy and safety profile found for R-115777 in MDS

Effective prevention of viral ARI found with CVT-E002 in elderly subjects